Altis Labs

We are excited to announce our $25 million Series A led by Tal Zaks at @OrbiMed and Anna French at @QimingUS

Read more about the news here: altislabs.com/news/altis-lab…

The reason this matters was presented in Seoul this week:

At the World Conference on Lung Cancer, Johnson & Johnson presented a post-hoc analysis of their Phase 3 MARIPOSA trial, showing that IPRO Response Rate, our AI endpoint, would have detected a significant treatment effect at Week 16… 11 months before the trial's primary efficacy analysis (progression-free survival) and 26 months before its final overall survival analysis.

The industry-standard imaging endpoint, objective response rate (ORR), did not anticipate the 12-month survival benefit the drug ultimately delivered, despite ORR being the primary endpoint in 42.6% of oncology drugs approved over the past 5 years.

Endpoints set the pace of drug development. An earlier, more reliable read on true clinical benefit lets drug developers stop ineffective therapies sooner and advance effective ones faster, reducing the time between a promising new treatment and the people whose lives depend on it.

IPRO reads the entire 3D scan rather than just the diameters of a handful of target lesions, and it is trained on the industry's most comprehensive real-world imaging, clinical, and outcomes database to predict what matters most: survival. Clinical trial sponsors use IPRO in active trials today to generate earlier efficacy signals and inform billion-dollar development decisions.

Thank you to our biopharma partners, new and existing investors, and hard-working team for advancing the field to accelerate drug development.

We’re excited to share that we have entered into a collaboration agreement with @JNJInnovMed.

Trained on the industry’s most comprehensive multimodal real-world dataset, our AI models will support the evaluation of novel outcome measures that have the potential to accelerate trial timelines, reduce costs, and improve evidence generation in drug development.

This collaboration reflects our commitment to accelerating clinical development with state-of-the-art AI.

At the Canadian Breast Cancer Symposium, we presented a first glimpse of IPRO’s ability to generalize across cancer types.

In this study, our AI model analyzed pretreatment breast cancer scans having trained solely on lung cancer data. Remarkably, IPRO stratified survival outcomes more effectively than traditional measures like TNM stage and patient age in this population.

These early results are a promising signal as we continue expanding our work across indications.

Thanks to Dr. Omar Khan and our co-authors from @UCalgary and @HamHealthSci for their collaboration on this work.

#breastcancer #ai #clinicaltrial

Link to poster: eps102.eposterscholar.com/epo/posters/21

We're proud to share that results from @AstraZeneca's evaluation of our AI-powered External Control Arm were presented at #ISPOR2025 today. AZ's analysis showed that our ECA replicated survival outcomes of the control arm and preserved the observed treatment effect.

Thank you @brittanytrang for featuring the recent results from @AstraZeneca's evaluation of our AI models.

We have a lot more work to do, but we're excited to begin to showcase how AI can accelerate clinical development with a stronger predictor of overall survival, the gold standard measure of efficacy in oncology trials.